Evaluation of Patients With Methicillin-Resistant Staphylococcus Aureus Hospital-Acquired Pneumonia Treated With Linezolid or Vancomycin

Pfizer188 enrolled

Overview

The objective of this study is to review the local management of patients with methicillin-resistant Staphylococcus aureus hospital-acquired pneumonia treated with vancomycin or linezolid with the goal to define if any difference exists among these antimicrobials in regard to clinical and economic outcomes.

Non-randomized, retrospective, observational study

Study Type

OBSERVATIONAL

Enrollment

188

Conditions

Methicillin-Resistant Staphylococcus Aureus (MRSA)Hospital-Acquired Pneumonia

Interventions

LinezolidDRUG

Patients with documented MRSA hospital-acquired or ventilator-associated pneumonia treated with linezolid according to routine medical care.

VancomycinDRUG

Patients with documented MRSA hospital-acquired or ventilator-associated pneumonia treated with vancomycin according to routine medical care.

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: Patients will be enrolled in the study if they fulfill the following three inclusion criteria: 1. Protocol criteria for HAP/VAP: Criteria for making a correct diagnosis of HAP will be met if the patient develops a new or progressive pulmonary infiltrate associated with at least two of the following: new or increased respiratory symptomatology (cough, sputum or tracheal secretions, shortness of breath), fever or hypothermia, leukocytosis, left shift, or leukopenia, or deterioration of pulmonary function. 2. Isolation of MRSA from a respiratory sample or blood culture within 48 hours of the diagnosis of HAP/VAP 3. Treatment of MRSA HAP/VAP with either vancomycin or linezolid with incorporation of 100 patients in the vancomycin arm and 100 patients in the linezolid arm Exclusion Criteria: Patients not meeting enrollment criteria.

Outcomes

Primary Outcomes

Percentage of Participants With Clinical Success

Clinical success was assessed as number of participants cured or improved. Cure = complete resolution of signs and symptoms of pneumonia; Improvement = partial resolution of signs and symptoms of pneumonia.

Time frame: 14 days after diagnosis with VAP or hospital discharge, whichever occurred first

Secondary Outcomes

Number of Participants With Microbiological Outcome

Microbiological outcome was defined as superinfections (infections diagnosed within 72 hours of the diagnosis of HAP and until day 28) and colonization (positive cultures with a multi-drug resistant organism).

Time frame: 28 days after diagnosis of VAP

Duration of Hospital Stay

Duration of hospital stay was assessed as number of days from VAP diagnosis to discharge from the hospital.